From Yahoo Finance · · 1m 10s
Geron Targets $240M RYTELO Revenue by 2026
Geron expects $230-240 million in 2026 RYTELO revenue as community adoption grows
In brief
Geron expects $230-240 million in 2026 RYTELO revenue as community adoption grows Geron's RYTELO revenue guidance rises to $240 million by 2026 with strong community oncology adoption Originally reported by Yahoo Finance.
2026 Revenue Update
Geron now expects $230-240 million in 2026 RYTELO revenue, toward the high end of its previous $220-240 million guidance.
“Geron expects 2026 RYTELO revenue of approximately $230 million to $240 million”
Record Quarterly Sales
The company reported $57.5 million in net revenue for the latest quarter, its highest since RYTELO's July 2024 launch.
“Geron reported $57.5 million in net revenue in its latest quarter”
Community Focus Shift
Geron is targeting community oncology practices for 80% of its lower-risk MDS market, adding 100-200 new accounts quarterly.
“Commercial efforts are shifting toward community oncology practices, which account for about 80% of the lower-risk MDS market”
Early-Line Growth
34% of Geron's business comes from first- and second-line patients, with expectations for growing early-line mix over time.
“34% of Geron's business, measured using a 12-month lookback, came from first- and second-line patients”
European Strategy
Geron plans to outline its European commercialization strategy before year-end without pursuing traditional country-by-country builds.
“Geron plans to provide an ex-U.S. strategy, particularly for Europe, before year-end”
Myelofibrosis Trial
The 327-patient IMpactMF Phase 3 trial for relapsed myelofibrosis compares imetelstat with best available therapy.
“Geron also discussed its IMpactMF Phase 3 trial in relapsed or refractory myelofibrosis following treatment with a JAK inhibitor”
Cash Reserves
Geron has over $300 million in cash and reiterated 2026 operating expense guidance of $230-240 million.
“Geron had more than $300 million in cash and recently hired its first chief business officer”
FDA Approval Impact
RYTelo received FDA panel approval in July 2024 as the first telomerase inhibitor for lower-risk MDS patients.
“RYTelo, or imetelstat, was launched in July 2024 as the first telomerase inhibitor for patients with lower-risk myelodysplastic syndromes”
The key point
Geron's RYTELO revenue guidance rises to $240 million by 2026 with strong community oncology adoption
